Compounded vs FDA-Approved Peptides: The Difference Explained

Patients hear that compounded peptides are "not FDA-approved" and reasonably ask: is that bad? The honest answer is more nuanced than yes-or-no — and the nuance is the entire point. Compounded medications are not FDA-approved because they are not manufactured products. They are individualized preparations made in response to a specific patient's prescription. That is a different regulatory category, not a worse version of the same one.

This article explains the difference precisely: what FDA approval actually certifies, what compounding actually is, the distinction between 503A and 503B pathways, how quality is controlled in each, and what the FDA has actually said about compounded peptides in 2026.

What FDA approval certifies

FDA approval of a drug product is the result of a New Drug Application (NDA) or Biologics License Application (BLA). The sponsor — usually a pharmaceutical company — submits a dossier covering:

• Chemistry, Manufacturing, and Controls (CMC) — the molecule, the manufacturing process, the specifications, the analytical methods, the stability data.
• Nonclinical pharmacology and toxicology — animal studies establishing safety margins.
• Clinical pharmacology — pharmacokinetics, pharmacodynamics in humans.
• Phase 1, 2, and 3 clinical trials — efficacy and safety in the target indication and population.
• Risk management — proposed labeling, REMS programs if applicable, post-market surveillance plan.

If the FDA approves the application, the agency grants approval for that specific drug, made by that specific manufacturer, by that specific process, for that specific indication and population. The approval is tied to the entire package.

What FDA approval certifies, in plain terms: this product, made this way, has been shown in trials to do what the label says, with a known safety profile in the studied population, manufactured under cGMP that the FDA has reviewed and inspected.

What FDA approval does not address: whether a different formulation of the same active ingredient, prepared individually for a specific patient by a licensed pharmacist, is appropriate for that patient. Compounding sits in a different framework, by design.

What compounding is

Compounding is the practice of preparing a medication that is tailored to the needs of an individual patient. It predates the FDA approval framework entirely — pharmacy compounding has been part of medical practice for centuries. Modern compounding is regulated, but the basic premise is the same: a licensed pharmacist, working from a valid prescription written by a licensed prescriber, prepares a medication for a specific patient.

Compounding exists for several reasons:

• The approved product is not commercially available — discontinuation, shortage, or for a niche population not large enough to justify a branded product.
• The patient cannot tolerate an inactive ingredient in the approved product (a dye, preservative, or excipient).
• The needed dose or strength is not commercially available — the approved product comes in fixed strengths and the patient needs a different one.
• The needed combination is not commercially available — multiple active ingredients combined for convenience.
• The needed delivery form is not commercially available — for example, an injectable form when only oral exists.

For peptides in 2026, the most common compounding rationales are individualized dosing (microdose protocols, slow-titration protocols), combination preparations, and access to peptides for which no branded product is currently on the market.

The two compounding pathways: 503A and 503B

The Drug Quality and Security Act (DQSA) of 2013 codified two compounding pathways with different scopes and different oversight.¹

Section 503A pharmacies

A 503A pharmacy is a traditional licensed pharmacy that compounds medications individually for specific patients with valid prescriptions. Defining features:

• Patient-specific — each preparation is made in response to a prescription for a named patient.
• State-board regulated — state pharmacy boards are the primary regulator. Some states have explicit compounding rules; the FDA may inspect under specific circumstances but does not routinely inspect 503A pharmacies.
• Beyond-use dating per USP — preparations carry a beyond-use date governed by USP standards (typically <797> for sterile preparations).
• Volume restrictions — 503A pharmacies cannot compound in advance of receiving prescriptions, except in limited "anticipatory compounding" volumes tied to a documented prescriber-patient relationship history.
• Cannot ship interstate beyond a 5% threshold — unless the pharmacy's home state is a signatory to a memorandum of understanding (MOU) with the FDA. (As of 2026, many states have entered MOUs that effectively expand the threshold.)

Section 503B outsourcing facilities

A 503B outsourcing facility is a registered facility that can compound larger volumes, often without patient-specific prescriptions, for distribution to healthcare providers (office stock). Defining features:

• FDA-registered and cGMP-compliant — registers directly with the FDA, follows current Good Manufacturing Practice standards, and is subject to FDA inspection.
• No patient-specific prescription required — can compound for office stock, although individual administration is still tied to a prescriber order.
• Can ship interstate without the 503A volume threshold restrictions.
• Cannot copy a commercially available approved drug — except under specific exceptions (e.g., during a confirmed FDA-listed shortage of the approved drug).

Both pathways produce non-FDA-approved preparations

Whether compounded by a 503A pharmacy or a 503B outsourcing facility, the resulting preparation is not an FDA-approved drug product. The pathway is the regulatory framework; the preparation is what is dispensed. Neither category produces an FDA-approved drug, because neither category goes through NDA/BLA approval — that is a different framework entirely.

This is the core of the confusion: a 503B facility is FDA-registered and FDA-inspected. That sounds like FDA approval. It is not. The facility is registered with the FDA; the product is not approved by the FDA. Two different things.

Why compounded peptides exist alongside approved peptides

For peptides specifically, several real-world dynamics drive use of compounded preparations alongside FDA-approved branded products:

Shortage-driven access. During FDA-listed shortages of branded GLP-1 drugs, 503A and 503B compounding of those molecules expanded under the shortage exception. As shortage status shifts, the compounding landscape responds. The DQSA's structure explicitly contemplates this scenario.

Individualized dosing. Branded GLP-1 products come in fixed dose pens (e.g., 0.25 mg, 0.5 mg, 1 mg, 2 mg, 2.4 mg for semaglutide brand products). A clinician aiming for 0.1 mg weekly — the kind of dose used in microdose protocols — cannot deliver that dose accurately from a fixed-strength pen, and the approved product was not designed for that use case. Compounded multi-dose vials with patient-specific dosing instructions accommodate it.

Peptides without branded products. Some peptides used in clinical practice — sermorelin acetate, for example — had FDA-approved branded products that were withdrawn from the market for non-safety reasons and remain available only through compounding. Others (CJC-1295, ipamorelin, BPC-157) were never FDA-approved as branded products at all, and exist only in compounded form when prescribed at all.

Combination preparations. A clinician may prescribe a combination — for example, a B12/MIC injection, or a sermorelin/ipamorelin combination — that does not exist as a single approved product. Compounding produces the combined preparation per the prescription.

In each of these cases, a clinician makes the individualized prescribing decision and a registered pharmacy fulfills it. The mechanism is the same; the rationale varies.

Quality control at a compounding pharmacy

The legitimate question patients ask is: how do I know a compounded preparation is what it says it is? Quality control at a registered compounding pharmacy operates at multiple layers.

API sourcing

The active pharmaceutical ingredient (API) used in compounding must come from an FDA-registered API supplier and meet USP grade specifications (or equivalent if no USP monograph exists). Pharmacies maintain Certificates of Analysis (CoA) for each lot of API received, documenting purity, identity, and contaminant testing.

For peptides specifically, this includes purity by HPLC, identity by mass spectrometry, water content, residual solvents, and (for sterile-source API) endotoxin levels.

USP standards

USP <797> governs sterile compounding — the standards for the cleanroom environment, personnel garbing, aseptic technique, beyond-use dating, sterility testing, and environmental monitoring. USP <800> governs handling of hazardous drugs. USP <795> governs nonsterile compounding. USP <1207> governs container closure integrity for parenteral products.

A pharmacy compounding sterile peptide injectables operates under <797> at minimum, with internal quality programs typically going beyond the minimum (e.g., environmental monitoring frequency, batch potency testing, third-party stability studies for specific preparations).

State board oversight

503A pharmacies are inspected by their state boards of pharmacy. Inspection scope and frequency vary by state, but typical elements include facility review, documentation review, beyond-use date practices, recall procedures, and complaint handling. Some states (e.g., California, Texas, Florida) have particularly active compounding oversight programs.

FDA oversight where applicable

503B facilities are inspected directly by the FDA on a routine cycle. The FDA also retains authority to inspect 503A pharmacies when concerns arise — through Form 483 inspections, warning letters, and (in serious cases) enforcement actions. The FDA's inspection database is publicly searchable.

Pharmacy-specific quality programs

Beyond regulatory minimums, individual pharmacies operate quality programs that include:

• Lot-level potency assay — testing each compounded lot to confirm the final preparation contains the labeled API concentration.
• Sterility testing — for sterile preparations, sterility verification per USP <71>.
• Endotoxin testing — for parenteral preparations, bacterial endotoxin testing per USP <85>.
• Stability studies — to assign and validate beyond-use dates.
• Container closure integrity — to confirm the vial/stopper system maintains sterility through the shelf life.

A pharmacy that publishes its quality program — testing protocols, third-party labs used, accreditations like PCAB — is a different proposition than one that does not.

What the FDA has actually said about compounded GLP-1s

The FDA's communications on compounded GLP-1s in recent years have been precise. Three threads run through them:²

Compounded versions are not FDA-approved. This is stated repeatedly and is correct. The compounded preparation has not been through NDA review. Patients should know this.

Adverse events tied to compounded products have been reported. Many of these involve patient self-administration errors — drawing the wrong volume from a multi-dose vial because the concentration differs from the patient's expectation based on the branded pen. The FDA flags this as a real safety concern, and prescribers should pay close attention to dispensing labels, syringe selection, and patient education.

Non-approved salt forms are a distinct concern. The FDA has issued specific guidance about preparations using "semaglutide sodium" or other salt forms not used in the approved drug — these are different chemical entities, not the API approved for the branded product. Reputable 503A and 503B compounders use the API form aligned with the approved drug; gray-market sources may not.

What the FDA has not done: declared that properly-prescribed, properly-dispensed compounded GLP-1s are illegal. The 503A/503B framework exists by federal statute, and the FDA's enforcement actions have been targeted at specific bad actors (non-approved salt forms, distribution without prescriptions, false marketing) rather than at compounding generally.

A clear-eyed comparison

Putting compounded and FDA-approved peptides side by side:

Dimension	FDA-approved peptide drug	Compounded peptide preparation
Regulatory pathway	NDA/BLA approval	503A patient-specific or 503B outsourcing
Pre-market trials	Yes, Phases 1–3	Not required for the preparation; API meets USP grade
Indication	Specific, labeled	Individualized per prescription
Dose flexibility	Fixed product strengths	Customized per prescription
Insurance	Often covered	Typically out-of-pocket
Manufacturer	FDA-inspected cGMP	503B: FDA-inspected cGMP; 503A: state-board oversight, USP standards
Adverse event reporting	FAERS	MedWatch and state board mechanisms
Prescription required	Yes	Yes
Post-market surveillance	Continuous	Pharmacy quality programs and complaint handling
Cost	Typically higher list price; insurance may apply	Typically lower list price; cash-pay

Neither column is universally better. They are different frameworks with different appropriate uses.

A patient with insurance coverage, a labeled indication, a standard dose, and access to the branded product is well-served by the approved pathway. A patient who needs a non-standard dose, a combination preparation, or a peptide without an approved branded product is the use case the compounding pathway exists to serve. The clinician — not the patient, not the marketing — should make the call.

Practical signals of legitimacy

When a patient is offered a "compounded peptide," several markers separate legitimate from gray-market:

• A real prescription, written by a licensed prescriber after a real evaluation.
• A named pharmacy with verifiable licensure and registration.
• A patient-labeled package identifying the prescriber, the patient, the API, the dose, and the beyond-use date.
• API from an FDA-registered supplier, with a Certificate of Analysis on file at the pharmacy.
• Sterile preparation under USP <797> for injectables.
• Cold-chain shipping when required.
• A clinician contact for follow-up and adjustment.

Any of those missing is a signal that the preparation did not pass through a legitimate compounding pharmacy — it is something else, sold using the language of compounding.

How TelePeptide handles compounded peptides

TelePeptide programs use compounded preparations from licensed 503A pharmacies for protocols where individualized dosing or specific peptide combinations are appropriate. The prescription is real; the prescriber is licensed in the patient's state; the pharmacy is registered; the preparation ships with a patient-specific label; the clinician remains involved through follow-up.

For molecules where an FDA-approved branded product is the right fit for the specific patient, the prescribing clinician may choose that pathway instead. The decision — compounded or branded, which dose, which monitoring cadence — sits with the clinician, not with the patient or the program defaults.

Compounded medications are prepared by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.

Footnotes

1. US Food and Drug Administration. Drug Quality and Security Act (DQSA), Pub. L. 113-54 (2013). https://www.fda.gov/drugs/human-drug-compounding/drug-quality-and-security-act-dqsa ↩

2. US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss ↩